F20 F25
Conditions
Interventions
Group 1: Patients with schizophrenia will be examined with respect to negative symptoms using psychopathological interviews, behavioral tasks and functional magnetic resonance imaging
Group 2: Healthy
Sponsors
Charité - Universitätsmedizin BerlinKlinik für Psychiatrie und Psychotherapie
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: In order to be eligible to participate in this study, all participants must meet all of the following criteria: • 18-60 years old • Written informed consent In patients the diagnostic criteria are: • DSM-5 diagnosis of schizophrenia on the basis of the Structured Clinical Interview for DSM-5 (SCID-I) • Clinical stability as judged by the treating psychiatrist and indicated by no change in medication in the two weeks prior to the initial assessment
Exclusion criteria
Exclusion criteria: Any potential subject who meets any of the following criteria will be excluded from participation in this study: • Any previous neurosurgery or neurological disorder, including epilepsy • History of head injury resulting in unconsciousness lasting at least 1 hour • Pregnancy or lactation • Any contraindications for MRI such as ferromagnetic/non-MRI-compatible items or medical devices on or in the body (for example pacemaker, brain stimulator, clips, metal implants) • sensorineural hearing loss of 30dB or more or history of tinnitus • Incompetency to fully comprehend the purpose of the study or to make a rational decision whether or not to participate In patients additional exclusion criteria are: • Benzodiazepine use of more than 1mg lorazepam equivalents per day • Comorbid axis-I disorder
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Strength of association between neural and behavorial markers with motivational negative symptoms | — |
Secondary
| Measure | Time frame |
|---|---|
| (1) The association between the neurobehavioral marker and apathy is reproducible across centers. (2) The association between the neurobehavioral marker and apathy is stable over the time of 3 months. (3) The neurobehavioral marker at the initial assessment will predict the level of negative symptoms 9 months later. | — |
Countries
Germany, Switzerland
Contacts
Public ContactFlorian Schlagenhauf
Charité-Universitätsmedizin Berlin
Outcome results
None listed